Understanding how EP300 mutations affect bladder cancer and treatment response
The Role of EP300 Mutations in Bladder Cancer Pathogenesis and Drug Response
This study is looking at how changes in the EP300 gene might make bladder cancer harder to treat with current medications, and it aims to find new ways to help patients respond better to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11027422 on NIH RePORTER |
What this research studies
This research investigates the role of EP300 gene mutations in bladder cancer, particularly how these mutations may contribute to resistance against current treatments like erdafitinib. The study aims to explore the biological effects of these mutations and their impact on the effectiveness of therapies targeting the IL-6-JAK1-STAT3 signaling pathway. By analyzing a large cohort of patients with urothelial cancer, the research seeks to identify potential strategies to overcome treatment resistance and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic bladder or upper tract urothelial cancer who have mutations in the EP300 gene.
Not a fit: Patients with non-metastatic bladder cancer or those without EP300 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with bladder cancer, particularly those who have developed resistance to existing therapies.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, suggesting that this approach may yield beneficial outcomes.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Solit, David B. — Sloan-Kettering Inst Can Research
- Study coordinator: Solit, David B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.